COMPASS Pathways plc
CMPSHealthcareNASDAQMedical Care Facilities · Last scanned Jun 1, 2026
Scan Results
Daily timeframeCOMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company carries a $1.76B market cap, placing it firmly in the small-cap category. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Market Cap
$1.76B
Beta
2.40
P/E (TTM)
—
P/E (Fwd)
-12.36
EPS (TTM)
$-3.14
EPS (Fwd)
$-1.06
ROE
-68.5%
ROA
-25.6%
Cash
$466.0M
Total Debt
$53.3M
Free CF
$33.1M
52W Change
198.9%
Annual Financials
Cash vs Debt
With $466.0M in cash and $53.3M in debt, CMPS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $33.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -68.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
COMPASS Pathways plc's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, CMPS has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence COMPASS Pathways plc's trajectory.